Tag Archives: Preclinical Indicators and Dementia

Summary of Recent Progress in Alzheimer’s Disease Prevention Trials (CTAD / JPAD)

Posted on October 1, 2018 by Dementia and Elderly Care News

Summary The following article summarises a round-up of present understanding and developments reflected in current and planned prevention trials, as discussed at a EU / US / Clinical Trials in Alzheimer’s Disease (CTAD) Task Force meeting, as of December 2016-7. … Continue reading →

New Drugs for Dementia (POST Note PN 535)

Posted on August 29, 2016 by Dementia and Elderly Care News

Summary The Parliamentary Office of Science and Technology (POST) has produced a briefing outlining some of the challenges in developing new drugs for dementia, explained in the context of ongoing UK and international research programmes. There is an extensive bibliography, … Continue reading →

Posted in Alzheimer's Society, Alzheimer’s Research UK, Antipsychotics, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Models of Dementia Care, National, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest | Tagged Academic Institutes in the UK, Academy of Social Sciences, Aducanumab (Biogen), Alzheimer’s Association, Alzheimer’s Research UK’s Drug Discovery Alliance, Behavioural and Psychological Symptoms of Dementia (BPSD), Big Data, Big Data Funding and Research, Big Pharma, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, BPSD: Behavioral and Psychological Symptoms of Dementia, British Psychological Society (BPS), Co-ordination and Data Analytics, Cognitive Health in Ageing Register for Investigations, Collaborative Projects, Collaborative Research, Dementia Consortium, Dementia Risk Prevention, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), DPUK: Dementias Platform UK, Drug Discovery Alliance, Drug Licensing Approval, Drugs for BPSD, Drugs for Cognitive Symptoms of Cognitive Decline and Dementia, EAMS: Early Access to Medicines Scheme, Early Access to Medicines Scheme, Effective Non-Drug Interventions, Etanercept, European Prevention of Alzheimer's Dementia Consortium (EPAD), European Prevention of Alzheimer’s Dementia Consortium, Identification of People At Risk of Dementia, International Collaborations, International Programmes, International Research, Join Dementia Research, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, New Drugs for Dementia (POST Note PN 535), NIHR Clinical Research Network, Observations & Trials in Dementia Research, Parliament, Parliamentary Office of Science & Technology, Parliamentary Office of Science & Technology (POST), Participation in Research, Patient Access to New Drugs, Pharmaceutical Industry, Pioglitazone, POST: Parliamentary Office of Science & Technology, Pre-Symptomatic Diagnosis of Dementia, Preclinical Biomarkers and Dementia, Preclinical Indicators and Dementia, Prevention, Public Participation in Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Mapping, Research Networks, Solanezumab (Eli Lilly), Symptom-Modifying Drugs for Dementia, UK Dementia Research Institute, UK Parliament, UK Patient Recruitment Initiatives, Verubecestat (Merck), Well-Being and Health for People With Dementia (WHELD) Program | Leave a comment

Further Press Releases and Documents Relating to the 2016 Alzheimer’s Association International Conference (Alzheimer’s Association International Conference)

Posted on August 1, 2016 by Dementia and Elderly Care News

Summary A list of press-releases is available relating to some of the main presentations at the Alzheimer’s Association International Conference, held in Toronto last week. Full Text Link Reference Alzheimer’s Association International Conference® 2016. List of Press Releases. [Toronto. Online]: … Continue reading →

Posted in Antipsychotics, Charitable Bodies, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Quick Insights, Statistics, Universal Interest | Tagged 2016 Alzheimer’s Association International Conference (AAIC®2016), ADAPT-FS Research Group, Alzheimer Disease Anti-inflammatory Prevention Trial (ADAPT), Alzheimer's and Dementia: The Journal of the Alzheimer's Association, Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT), Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study (ADAPT-FS), Alzheimer's Disease Neuroimaging Initiative, Alzheimer’s Association, Alzheimer’s Association AAIC Press Office, Alzheimer’s Association International Conference® (AAIC®) 2016, Alzheimer’s Disease and Related Dementias (ADRD) Milestones (United States), Alzheimer’s Disease Research in Ibero America, Amyotrophic Lateral Sclerosis (ALS), Australian Reduction in Use of Antipsychotics in Dementia Care, Avoidable Hospital Admissions, Avoidable Hospitalizations of People With Alzheimer’s Disease: Cost to Medicare (USA), Behavioural and Psychological Symptoms of Dementia (BPSD), Beta-Amyloid PET Imaging, Canadian Research: Advances in Dementia Care, Celecoxib, Celecoxib (Selective COX-2 Inhibitor), Centro de Investigatición y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), Dementia Risk Prevention, Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Dementia-Related Misdiagnosis, Dementia-Related Misdiagnosis (Male), Disclosure, Disclosure of Risk Marker Status, Disclosure Protocols for Disclosing APOE Genotype for Risk of Dementia, Epidemiology of Alzheimer's disease in Ibero America, Estudio Nacional de Salud y Envejecimiento en México (ENASEM), Ethical Challenges in Preclinical Alzheimer’s Disease Studies and Trials, Ethical Considerations, Ethical Dilemmas, Ethics, Ethics and Consent, Eye Tests for Detection of Memory Decline and Dementia, Flanders-Belgian Patient Group, Formal Education and Complex Work (Cognitive Reserve), French Three-City Study, Frontotemporal Lobar Degeneration (FTLD), Genome-Wide Association Studies, Genome-Wide Association Studies (GWAS), Genome-Wide Association Study, Genotyping, Ibero America, International Genomics of Alzheimer's Project (IGAP), Latin America, Low Testosterone and Risk of Dementia, Men Receiving Dementia-Related Misdiagnoses More Than Women, Mild Behavioral Impairment (MBI), Milestones for Care and Support in U.S. National Plan to Address Alzheimer's Disease, Naproxen, Naproxen (Nonselective Cyclooxygenase [COX] Inhibitor), Neurodegeneration, Neurodegenerative Disease Research, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), NSAIDS: Non-Steroidal Anti-Inflammatory Drugs, p.R47H rs75932628 in TREM2 (Encoding the Triggering Receptor Expressed on Myeloid Cells 2 Gene on Chromosome 6p21), Preclinical Alzheimer's Disease, Preclinical Biomarkers and Dementia, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Reduction of Systematic Sedation in Dementia Care, Research and Development, Research and Innovation, Research Commitment, Risk Prevention, Risk Reduction, Risk Reduction (Formerly Termed Prevention by WDC), SABE (Salud Bienestar y Envejecimiento), Single SNP Associations in Flanders-Belgian AD Cohort, Smell and Eye Tests for Detection of Memory Decline and Dementia, Smell Tests For Detection of Memory Decline and Dementia, SNP rs75932628, Stopping Systemic Sedation, Systemic Sedation, Tau Pathogenesis, Tau Therapeutic Strategies, Testosterone Depletion and Increased Risk of Dementia, Three-City Study, Treating People with Alzheimer’s Disease Increases Survival and Reduces Cost of Care (vs. Non-Treatment), TREM2 R47H as a Risk Factor, USA National Plan to Address Alzheimer's Disease, Vascular Care Intervention To Prevent Dementia | Leave a comment

European Medicines Agency Consultation on Pharmacological Treatments for Dementia (EMA)

Posted on February 3, 2016 by Dementia and Elderly Care News

Summary The European Medicines Agency (EMA) has released an updated draft guideline on medicines for the treatment of Alzheimer’s Disease and other types of dementia, for consultative feedback. Full Text Link Reference Consultation on revised guideline on medicines to treat … Continue reading →

Spatial Navigation Tests For Disorientation May Identify Preclinical Alzheimer’s Disease? (BBC News / Science / JGCR / Brain)

Posted on October 26, 2015 by Dementia and Elderly Care News

Summary A German study indicates that persons with a high genetic risk of developing Alzheimer’s Disease might be identified early by monitoring their performance in tests involving navigation through a virtual maze. Full Text Link Reference Virtual reality maze ‘predicts … Continue reading →

Posted in BBC News, Diagnosis, For Doctors (mostly), For Researchers (mostly), In the News, International, Quick Insights, Universal Interest | Tagged APOE e4 Carriers, APOE-4 Allele, Apoe-ε4 Allele, APOE-ε4 Carriers, Apolipoprotein E (APOE) e4 Allele, Apolipoprotein E (Apoe)-ε4 Genotype, At-Genetic-Risk Alzheimer's Disease, BBC Health News, Behavioural Biomarkers, Big Data, Bonn, Brain (Journal), Center for Economics and Neuroscience: University of Bonn, Computer Games, Conversion to Dementia From Prodromal Disease, Dementia, Dementia Research, Department of Clinical Educational and Health Psychology: University College London, Department of Clinical Neurosciences: University of Cambridge, Department of Electrical Engineering: University College London, Department of Epileptology: University of Bonn, Department of Neuropsychology: Ruhr-University Bochum, Department of Psychiatry: University of Cambridge, Department of Psychology: Ulm University, Department of Psychology: University of Bonn, Diagnosis, Differential Diagnosis, Digital Diagnostic Tools, Disorientation, Donders Institute for Brain Cognition and Behaviour: Radboud University, Early Detection of Preclinical Disease, Early-Onset Alzheimer's Gene, Early-Onset Dementia, Entorhinal Cortex, Entorhinal Dysfunction in Adults at Genetic Risk for Alzheimer’s Disease, Gamification, German Center for Neurodegenerative Diseases (DZNE), German Centre for Neurodegenerative Diseases (Bonn), Germany, Germany. Department of Epileptology: University of Bonn, Grid-Cell-Like Representations, Grid-Cell-Like Representations in Adults at Genetic Risk for Alzheimer’s Disease, HTC Vive iVR Equipment, Information Technology, Institute of Cognitive Neuroscience: Ruhr-University Bochum, Institute of Cognitive Neuroscience: University College London, Journal of Geriatric Care and Research (JGCR), MRC Cognition and Brain Sciences Unit: University of Cambridge, Netherlands, Neurodegenerative Disease, Non-Invasive Biomarkers, Pre-Dementia (MCI), Preclinical Alzheimer's Disease, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Prodromal Alzheimer's Disease, Radboud University, Risk Factors, Ruhr-University Bochum, Science (American Association for the Advancement of Science), Science Journal, Sea Hero Quest (SHQ) Game, Spatial Disorientation, Spatial Navigation Benchmarks, Spatial Navigation Tests of Disorientation, Ulm University, University College London, University of Bonn, University of Cambridge, Virtual Mazes | Leave a comment

Tag Archives: Preclinical Indicators and Dementia

European Medicines Agency Consultation on Pharmacological Treatments for Dementia (EMA)

Spatial Navigation Tests For Disorientation May Identify Preclinical Alzheimer’s Disease? (BBC News / Science / JGCR / Brain)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites